Oric Pharmaceuticals Inc

ORIC

10.780USD

-0.080-0.74%

Close 09/12, 16:00（ET）Quotes delayed by 15 min

Score

Industry at a Glance

Industry Ranking

154 / 507

Overall Ranking

297 / 4724

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 12 analysts

Strong Buy

Current Rating

18.100

Target Price

+66.67%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in improving patients' lives by overcoming resistance in cancer. It is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Its clinical-stage product candidates include ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 43.45.

Undervalued

The company’s latest PE is -5.69, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 93.19M shares, increasing 11.58% quarter-over-quarter.

Held by Andreas Halvorsen

Star Investor Andreas Halvorsen holds 6.57M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.02.

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.80.

Score

Industry at a Glance

Previous score

0.00

Change

0



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

The company’s current valuation score is 1.20, which is lower than the Biotechnology & Medical Research industry's average of 1.64. Its current P/E ratio is -5.41, which is -45.40% below the recent high of -2.96 and 5.35% above the recent low of -5.12.

Score

Industry at a Glance

Previous score

1.20

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 154/507

No Data

The company’s current earnings forecast score is 9.17, which is higher than the Biotechnology & Medical Research industry's average of 7.96. The average price target for Oric Pharmaceuticals Inc is 18.50, with a high of 25.00 and a low of 12.00.

Score

Industry at a Glance

Previous score

9.17

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 8.64, which is higher than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 11.02 and the support level at 9.23, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.61

Change

0.23

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated：2025-09-12

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 6.02. The latest institutional shareholding proportion is 110.15%, representing a quarter-over-quarter increase of 10.60%. The largest institutional shareholder is Andreas Halvorsen, holding a total of 6.57M shares, representing 6.77% of shares outstanding, with 7.77% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Nextech Invest, Ltd.

5.29M

--

EcoR1 Capital, LLC

3.42M

--

VR Adviser, LLC

6.60M

+107.28%

Viking Global Investors LP

Star Investors

6.57M

+48.33%

Pfizer Inc

5.38M

--

SR One Capital Management, LP

4.62M

--

New Enterprise Associates (NEA)

2.20M

+40.19%

Alkeon Capital Management LLC

3.34M

+2.66%

The Column Group LP

3.54M

--

BlackRock Institutional Trust Company, N.A.

4.40M

+1.38%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the Biotechnology & Medical Research mixed industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 3.12, which is lower than the Biotechnology & Medical Research industry's average of 3.51. The company's beta value is 1.62. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

Oric Pharmaceuticals Inc

ORIC

5.09 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Insmed Inc

INSM

7.28 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Stoke Therapeutics Inc

STOK

7.13 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

7.07 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Protagonist Therapeutics Inc

PTGX

7.04 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

7.01 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.